Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1613 1627 1629
This examiner grants 59% of resolved cases
Mikhail O'Donnel Robinson is an examiner in Tech Center 1600 and Art Unit 1613. He has 130 resolved cases. The allowance rate for these cases is 59.2 percent. This 59.2 percent rate is based on the 130 resolved cases and indicates the likelihood of success.
The interview lift is 42.1 percent. This 42.1 percent lift measures the increase in the allowance rate when an interview is conducted compared to cases without an interview. The median days to allowance is 1231. This 1231 day period is the median time for applications to reach a grant. The 42.1 percent interview lift is a high metric, suggesting that oral advocacy is effective. Practitioners should prioritize interviews to improve the 59.2 percent base allowance rate. The 1231 days to allowance provides a timeline for managing expectations. The 130 resolved cases ensure that these metrics are based on a sufficient volume of data.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18570555 | E3 Ligase Inhibitors and Methods of Use Thereof | Non-Final OA | The Regents of the University of California |
| 18707062 | SELECTION AND TREATMENT OF SUBJECTS HAVING A CIRCULATING MYELOID CELL INFLAMMATORY PHENOTYPE | Non-Final OA | The Board of Trustees of The Leland Stanford Junior University |
| 18893545 | SUBSTITUTED PYRAZOLO PIPERIDINE CARBOXYLIC ACIDS | Non-Final OA | Bayer Aktiengesellschaft |
| 18944707 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18787216 | INHIBITORS OF MUTANT IDH1 AND IDH2 | Non-Final OA | Board of Regents, The University of Texas System |
| 17604560 | COMPOUNDS AGAINST CANCER BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | Final Rejection | Board of Regents, The University of Texas System |
| 18504724 | HETEROARYL DIAMIDE IRE1/XBP1s ACTIVATORS | Non-Final OA | The Scripps Research Institute |
| 17936654 | METHOD OF TREATING OR AMELIORATING CANCERS DRIVEN BY RECEPTOR TYROSINE KINASE FUSION ONCOGENES, AND COMPOSITIONS FOR THE SAME | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18550571 | PLASMA KALLIKREIN INHIBITORS | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18554479 | AEROSOL-FORMING SUBSTRATE AND AEROSOL-GENERATING SYSTEM | Final Rejection | SHENZHEN FIRST UNION TECHNOLOGY CO., LTD. |
| 17920000 | DRUG ANTIBODY CONJUGATES | Final Rejection | PHARMA MAR, S.A. |
| 17433121 | MEDICINAL COMPOSITION HAVING EXCELLENT STABILITY | Non-Final OA | EA Pharma Co., Ltd. |
| 18053326 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | Final Rejection | SERVIER PHARMACEUTICALS LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy